The clinical management of type 2 Gaucher disease

Molecular Genetics and Metabolism

Volumn 114, Issue 2, 2015, Pages 110-122

  Weiss, Karin ^a   Gonzalez, Ashley N ^a   Lopez, Grisel ^a   Pedoeim, Leah ^a   Groden, Catherine ^a   Sidransky, Ellen ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Acute neuronopathic; Congenital ichthyosis; Gaucher disease; Hydrops fetalis; Lysosomal storage disorder; Palliative care

Indexed keywords

CHAPERONE; GLUCOSYLCERAMIDASE;

ANEMIA; CONGENITAL SKIN DISEASE; ENZYME REPLACEMENT; FAILURE TO THRIVE; FEEDING DIFFICULTY; FETUS HYDROPS; GAUCHER DISEASE; GENE THERAPY; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOSPLENOMEGALY; HUMAN; NEUROLOGIC DISEASE; PALLIATIVE THERAPY; PARENT COUNSELING; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; TERATOLOGY; THROMBOCYTOPENIA; TYPE 2 GAUCHER DISEASE; DEFICIENCY; DISEASE MANAGEMENT; GENETICS; GENOTYPE; INFANT; NEWBORN;

DISEASE MANAGEMENT; GAUCHER DISEASE; GENOTYPE; GLUCOSYLCERAMIDASE; HUMANS; INFANT; INFANT, NEWBORN;

EID: 84921652104     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.11.008     Document Type: Review

References (85)

1. Rosenbloom B.E., Weinreb N.J. Gaucher disease: a comprehensive review. Crit. Rev. Oncog. 2013, 18:163-175.
2. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol. Genet. Metab. 2004, 83:6-15. 10.1016/j.ymgme.2004.08.015.
3. Sidransky E. Gaucher disease: insights from a rare mendelian disorder. Discov. Med. 2012, 14:273-281.
4. Stone D.L., Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv. Pediatr. 1999, 46:409-440.
5. Tayebi N., Stone D.L., Sidransky E. Type 2 Gaucher disease: an expanding phenotype. Mol. Genet. Metab. 1999, 68:209-219. 10.1006/mgme.1999.2918.
6. Gupta N., Oppenheim I.M., Kauvar E.F., Tayebi N., Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol. Dis. 2011, 46:75-84. 10.1016/j.bcmd.2010.08.012.
7. Mignot C., Gelot A., Bessières B., Daffos F., Voyer M., Menez F., et al. Perinatal-lethal Gaucher disease. Am. J. Med. Genet. A 2003, 120A:338-344. 10.1002/ajmg.a.20117.
8. Tayebi N., Reissner K.J., Lau E.K., Stubblefield B.K., Klineburgess A.C., Martin B.M., et al. Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher's disease. Pediatr. Res. 1998, 43:571-578. 10.1203/00006450-199805000-00003.
9. Sidransky E., Fartasch M., Lee R.E., Metlay L.A., Abella S., Zimran A., et al. Epidermal abnormalities may distinguish Type 2 from Type 1 and Type 3 of Gaucher disease. Pediatr. Res. 1996, 39:134-141. 10.1203/00006450-199601000-00020.
10. Holleran W.M., Ginns E.I., Menon G.K., Grundmann J.-U., Fartasch M., McKinney C.E., et al. Consequences of B-glucocerebrosidase deficiency in epidermis. J. Clin. Invest. 1994, 93:1756-1764.
11. Hruska K.S., LaMarca M.E., Scott C.R., Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 2008, 29:567-583. 10.1002/humu.20676.
12. Tang N.L.S., Zhang W., Grabowski G.A., To K.F., Choy F.Y.M., Ma S.L., et al. Novel mutations in type 2 Gaucher disease in Chinese and their functional characterization by heterologous expression. Hum. Mutat. 2005, 26:59-60. 10.1002/humu.9348.
13. Stone D.L., Tayebi N., Orvisky E., Stubblefield B., Madike V., Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum. Mutat. 2000, 15:181-188.
14. Scott S.A., Edelmann L., Liu L., Luo M., Desnick R.J., Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum. Mutat. 2010, 31:1240-1250. 10.1002/humu.21327.
15. Koprivica V., Stone D.L., Park J.K., Callahan M., Frisch A., Cohen I.J., et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am. J. Hum. Genet. 2000, 66:1777-1786. 10.1086/302925.
16. Beutler E., Liebman H., Gelbart T., Stefanski E. Three Gaucher-disease-producing mutations in a patient with Gaucher disease: mechanism and diagnostic implications. Acta Haematol. 2000, 104:103-105. 10.1159/000039760.
17. Vithayathil J., Gibney G., Baxevanis A.D., Stubblefield B.K., Sidransky E., Tayebi N. Glucocerebrosidase mutation H255Q appears to be exclusively in cis with D409H: structural implications. Clin. Genet. 2009, 75:503-504. 10.1111/j.1399-0004.2009.01163.x.
18. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661. 10.1056/NEJMoa0901281.
19. Orvisky E., Park J.K., LaMarca M.E., Ginns E.I., Martin B.M., Tayebi N., et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype 2002, 76:262-270.
20. Farfel-Becker T., Vitner E.B., Pressey S.N.R., Eilam R., Cooper J.D., Futerman A.H. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease 2011, 20:1375-1386. 10.1093/hmg/ddr019.
21. Farfel-Becker T., Vitner E.B., Kelly S.L., Bame J.R., Duan J., Shinder V., et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 2014, 23:843-854. 10.1093/hmg/ddt468.
22. Vitner E.B., Salomon R., Farfel-Becker T., Meshcheriakova A., Ali M., Klein A.D., et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat. Med. 2014, 20:204-208. 10.1038/nm.3449.
23. Zhou W., Yuan J. Necroptosis in health and diseases. Semin. Cell Dev. Biol. 2014, 1-10. 10.1016/j.semcdb.2014.07.013.
24. Tylki-Szymańska A., Vellodi A., El-Beshlawy A., Cole J.A., Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J. Inherit. Metab. Dis. 2010, 33:339-346. 10.1007/s10545-009-9009-6.
25. Newman L.A., Keckley C., Petersen M.C., Hamner A. Swallowing function and medical diagnoses in infants suspected of dysphagia. Pediatrics 2001, 108:e106-e106. 10.1542/peds.108.6.e106.
26. Hanna R., McDonald M.T., Sullivan J.A., Mackey J.F., Krishnamurthy V., Kishnani P.S. Diagnostic and treatment challenges of neuronopathic Gaucher disease: two cases with an intermediate phenotype. J. Inherit. Metab. Dis. 2004, 687-690.
27. Tobias J.D., Atwood R., Lowe S., Holcomb G.W. Anesthetic considerations in the child with Gaucher disease. J. Clin. Anesth. 1993, 5:150-153.
28. Prows C.A., Sanchez N., Daugherty C., Grabowski G.A. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am. J. Med. Genet. 1997, 71:16-21. 10.1002/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.0.CO;2-O.
29. Mignot C., Doummar D., Maire I., De Villemeur T.B. Type 2 Gaucher disease: 15 new cases and review of the literature 2006, 28:39-48. 10.1016/j.braindev.2005.04.005.
30. Rapoport A. Sublingual atropine drops for the treatment of pediatric sialorrhea. J. Pain Symptom Manag. 2010, 40:783-788. 10.1016/j.jpainsymman.2010.02.007.
31. Erikson A., Bembi B., Schiffmann R. Neuronopathic forms of Gaucher's disease. Baillieres Clin. Haematol. 1997, 10:711-723.
32. Wusthoff C.J., Shellhaas R.A., Licht D.J. Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity. Pediatr. Clin. N. Am. 2007, 54:709-733. 10.1016/j.pcl.2007.06.004.
33. Chung C.-Y., Chen C.-L., Wong A.M.-K. Pharmacotherapy of spasticity in children with cerebral palsy. J. Formos. Med. Assoc. 2011, 110:215-222. 10.1016/S0929-6646(11)60033-8.
34. Park J.K., Orvisky E., Tayebi N., Kaneski C., LaMarca M.E., Stubblefield B.K., et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr. Res. 2003, 53:387-395. 10.1203/01.PDR.0000049515.79882.94.
35. Berg A.T., Baca C.B., Loddenkemper T., Dlugos D. Priorities in pediatric epilepsy research. Neurology 2013, 1166-1175.
36. Glass H.C. Neonatal seizures. Clin. Perinatol. 2014, 41:177-190. 10.1016/j.clp.2013.10.004.
37. Dulac O., Plecko B., Gataullina S., Wolf N.I. Occasional seizures, epilepsy, and inborn errors of metabolism. Lancet Neurol. 2014, 13:727-739. 10.1016/S1474-4422(14)70110-3.
38. Szlam S., Meredith M. Shake, rattle, and roll: an update on pediatric seizures. Pediatr. Emerg. Care 2013, 29:1287-1294.
39. Elias A.F., Johnson M.R., Boitnott J.K., Valle D. Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease. JIMD Rep. 2011, 5:95-98. 10.1007/8904_2011_104.
40. Barbier C., Devisme L., Dobbelaere D., Noizet O., Nelken B., Gottrand F. Neonatal cholestasis and infantile Gaucher disease: a case report. Acta Paediatr. 2002, 1399-1401.
41. Kelsey H., Christopoulos C., Gray A.A., Machin S.J. Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher's disease. J. Clin. Pathol. 1994, 162-165.
42. CE H., Levi M., Berends F., Aerts J.M., van Oers M.H. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br. J. Haematol. 1996, 470-476.
43. Gulhan B., Ozcelik U., Gurakan F., Gucer S., Orhan D., Cinel G., et al. Different features of lung involvement in Niemann-Pick disease and Gaucher disease. Respir. Med. 2012, 106:1278-1285. 10.1016/j.rmed.2012.06.014.
44. Erikson A., Johansson K., Mansson J.E., Scennerholm L. Enzyme replacement therapy of infantile Gaucher disease. Neuropediatrics 1993, 237-238.
45. Vellodi A., Tylki-Szymanska A., Davies E.H., Kolodny E., Bembi B., Collin-Histed T., et al. Management of neuronopathic Gaucher disease: revised recommendations. J. Inherit. Metab. Dis. 2009, 32:660-664. 10.1007/s10545-009-1164-2.
46. Elstein D., Abrahamov A., Zimran A. Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Clin. Genet. 1998, 54:179-184.
47. Bembi B., Ciana G., Zanatta M. Cerebrospinal-fluid infusion of alglucerase in the treatment for acute neuronopathic Gaucher's disease. Pediatr. Res. 1995, A425.
48. Lonser R.R., Walbridge S., Murray G.J., Aizenberg M.R., Vortmeyer A.O., Aerts J.M.F.G., et al. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann. Neurol. 2005, 57:542-548. 10.1002/ana.20444.
49. Lonser R.R., Schiffman R., Robison R.A., Butman J.A., Quezado Z., Walker M.L., et al. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology 2007, 68:254-261. 10.1212/01.wnl.0000247744.10990.e6.
50. Barranger J.A., Rapoport S.I., Fredericks W.R., Pentchev P.G., MacDermot K.D., Steusing J.K., et al. Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:481-485.
51. Schiffmann R., FitzGibbon E.J., Harris C., DeVile C., Davies E.H., Abel L., et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann. Neurol. 2008, 64:514-522. 10.1002/ana.21491.
52. Ito S., Pophali P., CO W., Koklanaris E.K., Superata J., Fahle G.A., et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant. 2013, 48:1313-1316. 10.1038/bmt.2013.49.
53. Ito S., Barrett A.J. Gauchers disease-a reappraisal of hematopoietic stem cell transplantation. Pediatr. Hematol. Oncol. 2013, 30:61-70. 10.3109/08880018.2012.762076.
54. Ringdén O., Groth C.G., Erikson A., Granqvist S., Mansson J.E., Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 1995, 59:864-870.
55. Machaczka M. Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease. Pediatr. Hematol. Oncol. 2013, 30:459-461. 10.3109/08880018.2013.793757.
56. Saranjam H., Chopra S.S., Levy H., Stubblefield B., Maniwang E., Cohen I.J., et al. A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders. Eur. J. Hum. Genet. 2013, 21:115-117. 10.1038/ejhg.2012.105.
57. Benko W.S., Hruska K.S., Nagan N., Goker-Alpan O., Hart P.S., Schiffmann R., et al. Uniparental disomoy of chromosome 1 causing concurrent Charcot-Marie-Tooth and Gaucher disesae type 3. Neurology 2008, 70:976-978. 10.1212/01.wnl.0000305963.37449.32.
58. Cabrera-Salazar M.A., DeRiso M., Bercury S.D., Li L., Lydon J.T., Weber W., et al. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE 2012, 7:e43310. 10.1371/journal.pone.0043310.
59. Wang R.Y., Bodamer O.A., Watson M.S., Wilcox W.R. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet. Med. 2011, 13:457-484. 10.1097/GIM.0b013e318211a7e1.
60. Suzuki Y. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev. 2013, 35:515-523. 10.1016/j.braindev.2012.12.002.
61. Giugliani R., Waldek S., Germain D.P., Nicholls K., Bichet D.G., Simosky J.K., et al. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol. Genet. Metab. 2013, 109:86-92. 10.1016/j.ymgme.2013.01.009.
62. Joosten A., Decroocq C., de Sousa J., Schneider J.P., Etame E., Bodlenner A., et al. A systematic investigation of Iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease. ChemBioChem 2014, 15:309-319. 10.1002/cbic.201300442.
63. Schonemann W., Gallienne E., Ikeda-Obatake K., Asano N., Nakagawa S., Kato A., et al. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease. ChemMedChem 2013, 8:1805-1817. 10.1002/cmdc.201300327.
64. Tiscornia G., Lorenzo Vivas E., Matalonga L., Berniakovich I., Barragan Monasterio M., Eguizabal C., et al. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum. Mol. Genet. 2013, 22:633-645. 10.1093/hmg/dds471.
65. Aflaki E., Stubblefield B.K., Maniwang E., Lopez G., Moaven N., Goldin E., et al. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci. Transl. Med. 2014, 6. (240ra73-240ra73). 10.1126/scitranslmed.3008659.
66. Parenti G., Pignata C., Vajro P., Salerno M.C. New strategies for the treatment of lysosomal storage diseases (review). Int. J. Mol. Med. 2012, 31:11-20. 10.3892/ijmm.2012.1187.
67. Hill D.L., Miller V., Walter J.K., Carroll K.W., Morrison W.E., Munson D.A., et al. Regoaling: a conceptual model of how parents of children with serious illness change medical care goals. BMC Palliat. Care 2014, 13:1-8. 10.1186/1472-684X-13-9.
68. Youngblut J.M., Brooten D. Perinatal and pediatric issues in palliative and end-of-life care from the 2011 Summit on the Science of Compassion. Nurs. Outlook 2012, 60:343-350. 10.1016/j.outlook.2012.08.007.
69. Macdonald M.E., Liben S., Carnevale F.A., Rennick J.E., Wolf S.L., Meloche D., et al. Parental perspectives on hospital staff members "acts of kindness and commemoration after a child's death. Pediatrics 2005, 116:884-890. 10.1542/peds.2004-1980.
70. Lui K., Commens C., Choong R., Jaworski R. Collodion babies with Gaucher's disease. Arch. Dis. Child. 1988, 63:854-856.
71. Stone D.L., Carey W.F., Christodoulou J., Sillence D., Nelson P., Callahan M., et al. Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch. Dis. Child. Fetal Neonatal Ed. 2000, 82:F163-F166.
72. Stone D.L., van Diggelen O.P., de Klerk J.B., Gaillard J.L., Niermeijer M.F., Willemsen R., et al. Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease? 1999, 7:505-509. 10.1038/sj.ejhg.5200315.
73. Haverkaemper S., Marquardt T., Hausser I., Timme K., Kuehn T., Hertzberg C., et al. Congenital ichthyosis in severe type II Gaucher disease with a homozygous null mutation. Neonatology 2011, 100:194-197. 10.1159/000324116.
74. Chan A., Holleran W.M., Ferguson T., Crumrine D., Goker-Alpan O., Schiffmann R., et al. Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications. Mol. Genet. Metab. 2011, 104:631-636. 10.1016/j.ymgme.2011.09.008.
75. Reissner K., Tayebi N., Stubblefield B.K., Koprivica V., Blitzer M., Holleran W., et al. Type 2 Gaucher disease with hydrops fetalis in an Ashkenazi Jewish family resulting from a novel recombinant allele and a rare splice junction mutation in the glucocerebrosidase locus. Mol. Genet. Metab. 1998, 63:281-288. 10.1006/mgme.1998.2675.
76. Church H.J., Cooper A., Stewart F., Thornton C.M., Wraith J.E. Homozygous loss of a cysteine residue in the glucocerebrosidase gene results in Gaucher's disease with a hydropic phenotype. Eur. J. Hum. Genet. 2004, 12:975-978. 10.1038/sj.ejhg.5201251.
77. Zhao H., Keddache M., Bailey L., Arnold G., Grabowski G. Gaucher's disease: identification of novel mutant alleles and genotype-phenotype relationships. Clin. Genet. 2003, 64:57-64.
78. Michelakakis H., Dimitriou E., Moraitou M., Valari M., Yatrakou E., Mitsiadi V., et al. Perinatal lethal form of Gaucher disease. Clinical and molecular characterization of a Greek case. Blood Cells Mol. Dis. 2010, 44:82-83. 10.1016/j.bcmd.2009.11.007.
79. Chabás A., Gort L., Díaz-Font A., Montfort M., Santamaría R., Cidrás M., et al. Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]/P182L genotype: effect of the E326K change in neonatal and classic forms of the disease. Blood Cells Mol. Dis. 2005, 35:253-258. 10.1016/j.bcmd.2005.04.007.
80. Sinclair G., Choy F.Y., Humphries L. A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease. Blood Cells Mol. Dis. 1998, 24:420-427. 10.1006/bcmd.1998.0210.
81. Goker-Alpan O., Schiffmann R., Park J.K., Stubblefield B.K., Tayebi N., Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J. Pediatr. 2003, 143:273-276. 10.1067/S0022-3476(03)00302-0.
82. Aviner S., Garty B.-Z., Rachmel A., Baris H.N., Sidransky E., Shuffer A., et al. Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare. Blood Cells Mol. Dis. 2009, 43:294-297. 10.1016/j.bcmd.2009.08.004.
83. Rowlands S., Murray H. Prenatal ultrasound findings in a fetus diagnosed with Gaucher's disease (type 2) at birth. Prenat. Diagn. 1997, 17:765-769. 10.1002/(SICI)1097-0223(199708)17:8<765::AID-PD122>3.0.CO;2-3.
84. Sidransky E., Tayebi N., Stubblefield B.K., Eliason W., Klineburgess A., Pizzolato G.P., et al. The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease. J. Med. Genet. 1996, 33:132-136.
85. Sidransky E., Sherer D.M., Ginns E.I. Gaucher Disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr. Res. 1992, 32:1-5.